Skip header and navigation

65 records – page 1 of 7.

Document Type
Table
Review Code
EPM052101 RR Table
Question Submitted
May 21, 2020
Date Completed
May 25, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Document Type
Table
Review Code
EPM052101 RR Table
Question Submitted
May 21, 2020
Date Completed
May 25, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Category
Clinical Presentation
Epidemiology
Subject
Mortality
Hospitalization
Priority Level
Level 2 completed within 8 hours
Cite As
Williams-Roberts, H; Basran, J; Dalidowicz, M; Mueller, M. What are the fatality rates associated with COVID-19 for ICU, hospitalized, and patients discharged from ICU to general wards? 2020 May 25; Document no.: EPM052101 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. (CEST table)
Related Documents
Documents

EPM052101 RR Table

Download File
Less detail
Document Type
Evidence Search Report
Review Code
EOC211203 ESR
Question Submitted
December 23, 2021
Date Completed
December 30, 2021
Status
6. Cancelled
Research Team
EOC
to describe the epidemiology of persons with suspected SARS-CoV-2 infection, and the characteristics
Document Type
Evidence Search Report
Review Code
EOC211203 ESR
Question Submitted
December 23, 2021
Date Completed
December 30, 2021
Status
6. Cancelled
Research Team
EOC
Notes
No rapid review planned for this search.
Category
Epidemiology
Infection Prevention and Control
Population
All
Priority Level
Level 2 One week (7 days)
Cite As
Young, C; Dalidowicz, M. How are rapid antigen tests being used in different settings? What is the evidence on the impact of the use of rapid antigen tests on COVID-19 outbreak parameters?? 2021 Dec 30, Document no.: EOC211203 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 115 p. (CEST rapid review report).
Related Documents
Documents
Less detail
Document Type
Table
Review Code
INF031801v019 RR Table
Question Submitted
March 18, 2021
Date Completed
December 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Dr. Bruce Reeder, Community Health and Epidemiology Department, College of Medicine, University
Document Type
Table
Review Code
INF031801v019 RR Table
Question Submitted
March 18, 2021
Date Completed
December 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Immunity
Infection Prevention and Control
Clinical Presentation
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Jagwani, M; Lee, S; Shumilak, G; Reeder, B; Groot, G; Hernandez, L; Howell-Spooner, B; Miller, L. How effective are COVID-19 vaccines? 2021 Dec 26; Document no.: INF031801v019 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST Table)
Similar Reviews
EOC011901 RR
EOC031001 RR
Review History
INF031801v17 RR: November 23, 2021
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents

INF031801v019 RR Table

Download File
Less detail
Document Type
Rapid Review
Review Code
INF031801v019 RR
Question Submitted
March 18, 2021
Date Completed
December 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Document Type
Rapid Review
Review Code
INF031801v019 RR
Question Submitted
March 18, 2021
Date Completed
December 26, 2021
Status
5. Updated review
Research Team
Infectious Disease
Updated Key Findings
December 14, 2021
Ontario Immunization Advisory Committee recommended that if an 11 and 12-year-old child is inadvertently given a second dose of the Pfizer-BioNTech vaccine that is not authorized for their age, the dose should be considered valid and the series complete.
National Advisory Committee on Immunization (NACI) recommends that a booster dose of an authorized mRNA COVID-19 vaccine should be offered to vulnerable population and > 50 years old, =6 months after completion of a primary COVID-19 vaccine series.
Australian Technical Advisory Group on Immunization (ATAGI) recommends COVID-19 booster vaccination with either Pfizer (Comirnaty) or Moderna (Spikevax), which are considered equally acceptable, for anyone aged 18 and older who completed their primary course of COVID-19 vaccination 5 or more months ago.
On December 8th, 2021 in a press release by Pfizer-BioNTech said that preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 vaccine neutralize the Omicron variant while two doses show significantly reduced neutralization titers. Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses.
Key Findings
December 3, 2021
The Therapeutic Goods Administration (TGA) has granted provisional approval to Moderna for the use of its vaccine in children (two 10µg doses) and as booster shot for adults (one 30µg dose) in preparation for the recent emergence of the Omicron variant. This is in addition to Pfizer, which was also recently approved.
The National Advisory Committee on Immunization (NACI) recommends that a complete series with the Pfizer-BioNTech COVID-19 vaccine (10 mcg) may be offered to children 5-11 years of age who do not have contraindications to the vaccine, with a dosing interval of at least 8 weeks between the first and second dose.
NNACI also recommends that children aged 5-11 years with a history of previous SARS-CoV-2 infection should be considered no longer infectious and symptoms of an acute illness should be completely resolved prior to vaccination.
Health Canada has authorized Moderna's COVID-19 vaccine (also known as Spikevax) to be used as a booster shot, using a half-dose of the vaccine.
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Immunity
Infection Prevention and Control
Clinical Presentation
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Jagwani, M; Lee, S; Shumilak, G; Reeder, B; Groot, G; Hernandez, L; Howell-Spooner, B; Miller, L. How effective are COVID-19 vaccines? 2021 Dec 26. Document no.: INF031801v019 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 93 p. (CEST rapid review report)
Review History
INF031801v17 RR: November 23, 2021
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
INF031801v020 ESR
Question Submitted
March 18, 2021
Date Completed
January 14, 2022
Status
5. Updated review
Research Team
Infectious Disease
Document Type
Evidence Search Report
Review Code
INF031801v020 ESR
Question Submitted
March 18, 2021
Date Completed
January 14, 2022
Status
5. Updated review
Research Team
Infectious Disease
Category
Epidemiology
Infection Prevention and Control
Subject
Vaccines
Infection Prevention and Control
Clinical Presentation
Immunity
Population
All
Clinical Setting
Community
ICU
Medicine Unit
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Miller, L., Howell-Spooner, B. How effective are COVID-19 vaccines? 2022 Jan 14, Document no.: INF031801v020 ESR . In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 9 p. (CEST evidence search report).
Similar Reviews
EOC220304
Review History
INF031801v17 RR: November 23, 2021
INF031801v16 RR: November 12, 2021
INF031801v15 RR: October 28, 2021
INF031801v014 RR: October 16, 2021
INF031801v013 RR: September 24, 2021
INF031801v012 RR: September 10, 2021
INF031801v010 RR: August 25, 2021
INF031801v9 RR: August 23, 2021
INF031801v8 RR: August 9, 2021
INF031801v7 RR: July 20, 2021
INF031801v6 RR: July 2, 2021
INF031801v5 RR: June 22, 2021
INF031801v4 RR: June 3, 2021
INF031801v3 RR: May 24, 2021
INF031801v2 RR: May 14, 2021
INF031801 RR: March 31, 2021
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
INF121501-01 ESR
Question Submitted
December 15, 2020
Date Completed
December 15, 2020
Status
3. Completed
Research Team
Infectious Disease
, Rohela GK. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential
Document Type
Evidence Search Report
Review Code
INF121501-01 ESR
Question Submitted
December 15, 2020
Date Completed
December 15, 2020
Status
3. Completed
Research Team
Infectious Disease
Category
Epidemiology
Infection Prevention and Control
Subject
Transmission
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Miller, L; Fox, L. How is COVID-19 transmitted from person-to-person and what is the most common source of transmission? 2020 Dec 15; Document no.: INF121501-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 16 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
INF121501 RR
Question Submitted
December 15, 2020
Date Completed
December 17, 2020
Status
3. Completed
Research Team
Infectious Disease
Document Type
Rapid Review
Review Code
INF121501 RR
Question Submitted
December 15, 2020
Date Completed
December 17, 2020
Status
3. Completed
Research Team
Infectious Disease
Key Findings
· A recent evidence synthesis was completed by Public Health Ontario to answer a similar question. That synthesis has been deemed of sufficiently high quality and contains a recent enough evidence review to provide the necessary information to answer the question. Please refer to the attached document for the Key Points · We have reviewed the literature identified by our search that has been published since the time of the literature review in the Public Health Ontario evidence synthesis (i.e., between Oct 14, 2020 and Dec 15, 2020). No significant changes to the Key Points are noted. · Our team agrees with the conclusion of Public Health Ontario that the dominant mechanism of transmission is primarily through direct contact with respiratory droplets but that COVID-19 is an opportunistic airborne Rapid Review Report: INF121501 RR (Version 1: December 17, 2020 17:30) 2 pathogen, where aerosol transmission occurs under the right combination of conditions (for instance a poorly ventilated space where a high volume of virus can be produced and concentrated).
Category
Epidemiology
Infection Prevention and Control
Subject
Transmission
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Vanstone, J; Miller, L; Fox, L. How is COVID-19 transmitted from person-to-person and what is the most common source of transmission? 2020 Dec 15; Document no.: INF121501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 11 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Table
Review Code
INF121501 RR Table
Question Submitted
December 15, 2020
Date Completed
December 17, 2020
Status
3. Completed
Research Team
Infectious Disease
to the epidemiology of COVID-19 is unclear." -"Routes of transmission that are theoretically possible due
Document Type
Table
Review Code
INF121501 RR Table
Question Submitted
December 15, 2020
Date Completed
December 17, 2020
Status
3. Completed
Research Team
Infectious Disease
Category
Epidemiology
Infection Prevention and Control
Subject
Transmission
Population
All
Clinical Setting
Community
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Vanstone, J; Miller, L; Fox, L. How is COVID-19 transmitted from person-to-person and what is the most common source of transmission? 2020 Dec 17; Document no.: INF121501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. (CEST table)
Related Documents
Documents

INF121501 RR Table

Download File
Less detail
Document Type
Table
Review Code
EOC211201 RR Table
Question Submitted
December 23, 2021
Date Completed
January 12, 2022
Status
3. Completed
Research Team
EOC
Document Type
Table
Review Code
EOC211201 RR Table
Question Submitted
December 23, 2021
Date Completed
January 12, 2022
Status
3. Completed
Research Team
EOC
Category
Diagnostics
Epidemiology
Subject
Antigens
Infection Prevention and Control
Testing
Population
All
Clinical Setting
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Badea, A; Reeder, B; Groot, G; Muhajarine, N; Minion, J; Miller, L; Howell-Spooner, B. In real world settings, what is the validity of Rapid Antigen Tests (RATs) in identifying SARS-CoV-2 and how well do they predict disease? 2022 Jan 12, Document no.: EOC211201 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. (CEST table).
Related Documents
Documents

EOC211201 RR Table

Download File
Less detail
Document Type
Rapid Review
Review Code
EOC211201 RR
Question Submitted
December 23, 2021
Date Completed
January 12, 2022
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC211201 RR
Question Submitted
December 23, 2021
Date Completed
January 12, 2022
Status
3. Completed
Research Team
EOC
Key Findings
January 12, 2022
The diagnostic accuracy of Rapid Antigen Tests (RAT) has been widely studied in various applications and in diverse populations.
Sensitivity, in the order of 75% in pooled estimates, is significantly influenced by the presence or absence of symptoms, viral load, and the timing of sampling relative to the onset of symptoms.
Specificity, in the order of 99% in pooled estimates, is consistently high across tests, populations, and sampling methods.
Post-test probability of being an infectious case following a positive test is highest in individuals with a high pre-test probability (population prevalence > 5%), such as those with COVID-19 symptoms, and those in settings with a high level of community transmission. Here, the positive predictive value is in the order of 95%. However, when used in settings with a lower pre-test probability (population prevalence < 0.5%), as in screening asymptomatic individuals, the positive predictive value is considerably reduced, as low as 25%.
Post-test probability of being an infectious case following a negative test is less than 1% (negative predictive value > 99%) in all settings except those with the highest levels of community transmission.
Category
Diagnostics
Epidemiology
Subject
Antigens
Infection Prevention and Control
Testing
Population
All
Clinical Setting
Public Health
Priority Level
Level 2 One week (7 days)
Cite As
Badea, A; Reeder, B; Groot, G; Muhajarine, N; Minion, J; Miller, L; Howell-Spooner, B. In real world settings, what is the validity of Rapid Antigen Tests (RATs) in identifying SARS-CoV-2 and how well do they predict disease? 2022 Jan 12, Document no.: EOC211201 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 15 p. (CEST rapid review report).
Related Documents
Documents
Less detail

65 records – page 1 of 7.